Samarth Kulkarni - 26 Oct 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
26 Oct 2022
Transactions value $
-$949,175
Form type
4
Filing time
28 Oct 2022, 17:43:56 UTC
Previous filing
30 Sep 2022
Next filing
30 Nov 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $317K +19.6K +6.75% $16.21 310K 26 Oct 2022 Direct
transaction CRSP Common Shares Options Exercise $104K +5.42K +1.75% $19.12 315K 26 Oct 2022 Direct
transaction CRSP Common Shares Sale -$132K -2.5K -0.79% $52.73 313K 26 Oct 2022 Direct F1, F2
transaction CRSP Common Shares Sale -$216K -4K -1.28% $54.06 309K 26 Oct 2022 Direct F1, F3
transaction CRSP Common Shares Sale -$622K -11.3K -3.66% $54.97 297K 26 Oct 2022 Direct F1, F4
transaction CRSP Common Shares Sale -$400K -7.19K -2.42% $55.69 290K 26 Oct 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -19.6K -58.75% $0.00 13.8K 26 Oct 2022 Common Shares 19.6K $16.21 Direct F6
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -5.42K -2.08% $0.00 255K 26 Oct 2022 Common Shares 5.42K $19.12 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.29 to $53.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.43 to $54.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.45 to $55.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.45 to $56.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017.
F7 This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018.